


CATEGORY A

SMTA2 and other agreements with vaccine & antiviral manufacturers



SMTA2 NEGOTIATING STRATEGY AND ACHIEVEMENTS

Through the 17 SMTA2s and one Section 6.8 PIP Framework Agreement, WHO has secured approximately 11% of estimated future pandemic vaccine production that it will be able to send to countries in need at the time of the next pandemic. In addition, WHO will have access to up to 5 million treatment courses of antivirals.



VACCINE MANUFACTURERS AT-A-GLANCE



Estimate based on the use of existing technologies — figures may vary depending on the use of newer technologies

This milestone was achieved through WHO's strategic approach to focus on concluding agreements with the largest influenza vaccine manufacturers first. These manufacturers were targeted not only for their size but also because they have export experience and prequalified products, so when pandemic vaccine production begins, they will be able to supply vaccine the most rapidly to WHO. All vaccines and other pandemic products must be prequalified in order to be supplied to a UN agency such as WHO.

More information about the WHO Prequalification Program: <http://www.who.int/mediacentre/factsheets/fs278/en/>

This strategy has been successful, and to date WHO has concluded an SMTA2 with all the large multinational companies.

WHO will continue to conclude SMTA2s with all remaining influenza vaccine manufacturers.

Commitments to date

COMPANY	COMMITMENTS							
	Vaccine donation*	Vaccine reservation*	Antiviral donation	Antiviral reservation	Technology transfer to developing countries	Technology transfer to WHO	Gap Grantee	Pre-qualified Vaccine
Adimmune Corporation	8%	2%						
China National Biotech Group	8%	2%						
Denka Seiken	8%	2%						
F. Hoffmann-La Roche			≤5 M					
Glaxo Group Limited	8%	2%						
Government Pharmaceutical Organization	5%	5%					X	
Green Cross Corporation	7%	3%					X	X
Daiichi Sankyo Company Limited	8%	2%						
KM Biologics Co., Ltd.	8%	2%						
AstraZeneca Pharmaceuticals LP	9%	1%						X
The Research Foundation for Microbial Diseases for Osaka University (BIKEN)	8%	2%						
Sanofi Pasteur	7.5%	7.5%						X
Seqirus UK Limited	10%	2.5%						X
Serum Institute of India	8%	2%					X	X
Sinovac Biotech Co	8%	2%						
Takeda Pharmaceutical Company Limited	8%	2%						
Zydus Lifesciences Limited	8%	2%						
SK bioscience Co., Ltd.	8%	2%						

*Percentage of real-time pandemic vaccine production

Updated as of: 30 March 2026